New horizons in systemic therapy of acne
https://doi.org/10.33667/2078-5631-2019-2-26(401)-87-92
Abstract
According to some authors, systemic corticosteroids can be used at the beginning of the course of treatment, which helps to accelerate the achievement of a significant effect and reduces the severity of side effects of retinoids. However, many issues of the combined use of isotretinoin and systemic corticosteroids in terms of the methodological approach remain unclear, which determined the purpose of this research.
Material and methods. We observed 84 patients with moderate to severe acne. Among them, 51 (60.7 %) women and 33 (39.3 %) men, the average age of the patients was 17.1 ± 1.8 years. Patients were divided into 2 groups: moderate severe course — 1 group (n = 40), severe acne — 2 group (n = 44). Within the groups, depending on the therapy, the patients were divided into 2 subgroups: A subgroup — received isotretinoin in standard dosages, B subgroup — received isotretinoin also in standard dosages, while the initiation of therapy was carried out while taking systemic corticosteroid (1 month dexamethasone was prescribed at a dose 1 mg / day in 1 dose (in the morning)).
The results of the study. The dynamics of the DICI index, the global IGA score, DICI showed comparable efficacy results in long-term follow-ups and early differences, an advantage was noted in the groups treated with dexetozone.
Findings. Systemic retinoid is effective in preventing the formation of post-acne scars, which allows us to recommend it as the first choice in patients with risk factors for scar development. Important factors in the effectiveness of isotretinoin and the prevention of relapse are individual dose selection, the total cumulative and single dose and the duration of therapy for at least 6 months. The data obtained showed that the administration of a systemic corticosteroid in low doses (1 mg / day of dexamethasone) for 1 month of taking isotretinoin improves the effectiveness of therapy in the early stages of therapy and reduces the frequency / severity of side effects of retinoids.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Moscow
Russian Federation
Moscow
N. V. Gryazeva
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Moscow
Russian Federation
Moscow
A. R. Nazarenko
Moscow Scientific and Practical Centre for Dermatovenereology and Cosmetology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Круглова Л. С., Талыбова А. М., Глузмина М. М. Акне и сиптомокомплекс постакне: клиническая картина и методы терапии. Кремлевская медицина. Клинический вестник. — 2018. — № 1. — С. 21–26.
2. Thlboutot D, Gollnick H, Bettoli V, et al. New insights Into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009; 60: S 1–S 50.
3. Paugam C, Corvee S, Saint-Jean M, et al. Propionibacterium acnés phylotypes and acne severity: an observational prospective study. J Eur Acad Dermatol Venereol. 2017; 31: e398–e399.
4. Tan JK, Tang J, Fung K, et al. Prevalence and seventy of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008; 7: 551–556.
5. Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the Unites States. J Drugs Dermatol. 2017; 16: 97–102.
6. Thiboutot et al. Practical management of acne for clinicians: an international consensus from Global Alliance to improve outcomes in acne. J Am Acad Dermatol, 2018; 78: Sl-23.
7. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74: 945–973. e33.
8. Thielitz A, Flelmdach M, Ropke EM, Gollnick FI. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001; 145: 19–27.
9. Gollnick HP, Bettoll V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016; 30 (9): 1480–1490.
10. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997; 194: 351–357.
11. Tan J, Knezevic S, Boyal S, Waterman B, Janik T. Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120– 150 mg/kg. J Cutan Med Surg. 2016; 20: 13–20.
12. Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016; 55: 518–523.
13. Круглова Л. С., Талыбова А. М., Грязева Н. В. Эффективность применения системного препарата на основе изотретиноина при различной степени тяжести акне // РМЖ. Медицинское обозрение. 2018. № 4. С. 53–56.
14. Lehucher-Ceyrac D, de La Salmoniere P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology. 1999; 198: 278–283.
15. Ballanger F, Baudry P, N’Guyen JM, Khammari A, Dreno B. Heredity: a prognostic factor for acne. Dermatology. 2006; 212: 145–149.
16. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006; 54: 644–646.
17. Dreno B, Bettoli V, Ochsendorf F, et al. An expert view on the treatment of acne with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol. 2006; 16565–571.
Review
For citations:
Kruglova L.S., Gryazeva N.V., Nazarenko A.R. New horizons in systemic therapy of acne. Medical alphabet. 2019;2(26):87-92. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-26(401)-87-92
Views:
981
Email this article 